MONTREAL, QUEBEC--(Marketwire - May 13, 2008) - Ambrilia Biopharma Inc. (TSX: AMB) announced today that it will be hosting a conference call and webcast tomorrow, May 14, 2008, at 9:00 am ET, to discuss the 24-week results of the Phase III efficacy and safety study (Study 301) for its prolonged release formulation of Octreotide C2L. Prior to the conference call, a press release will be issued at approximately 7:00 am ET.
